Vimarsana
Biggest News Aggregation in the World

Page 8 - Rqol News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Rqol. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Rqol Today - Breaking & Trending Today

Health-Related Quality of Life: A Vital Health Assessment Tool - Vimarsana News

Health-Related Quality of Life: A Vital Health Assessment Tool

Health-Related Quality of Life (HRQOL) is a multidimensional dynamic concept that includes physical, mental and emotional well-being, as well as optimal social functioning and interaction with the environment.

Multiple Benefits of Mindfulness for Migraine, RCT Shows - Vimarsana News

Multiple Benefits of Mindfulness for Migraine, RCT Shows

A mindfulness-based treatment has shown multiple benefits in patients with chronic migraine and medication-overuse headaches, results of a new randomized trial show.

Transcatheter Tricuspid Repair Improved Quality of Life - Vimarsana News

Transcatheter Tricuspid Repair Improved Quality of Life

Transcatheter tricuspid repair reduced valve regurgitation and improved quality of life at 1 year even for the sickest patients, but mortality remained high, new analysis of TRILUMINATE trial shows.

Exercise Plan Cost-Effective in Post-Stroke Cognitive Rehab - Vimarsana News

Exercise Plan Cost-Effective in Post-Stroke Cognitive Rehab

An exercise program improved cognitive scores and yielded cost savings, according to a recent study, but showed limited effects on health-related quality of life.

Ide-Cel Provides HRQOL Benefits Over Standard Regimens in R/R Multiple Myeloma - Vimarsana News

Ide-Cel Provides HRQOL Benefits Over Standard Regimens in R/R Multiple Myeloma

Idecabtagene vicleucel resulted in meaningful improvements in symptoms, functioning, overall health status, and health-related quality of life vs standard regimens in select patients with triple-class exposed relapsed/refractory multiple myeloma, according to updated data from the phase 3 KarMMa-3 trial.